Surrozen (NASDAQ:SRZN – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.
Several other equities analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a report on Thursday, October 15th. Guggenheim set a $80.00 target price on Surrozen and gave the company a “buy” rating in a report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $54.00 target price (up from $44.00) on shares of Surrozen in a research report on Friday, September 25th. William Blair assumed coverage on Surrozen in a research report on Thursday, August 20th. They issued an “outperform” rating and a $51.00 target price for the company. Finally, Zacks Research upgraded Surrozen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $61.75.
Check Out Our Latest Stock Report on SRZN
Surrozen Stock Down 0.2%
Surrozen (NASDAQ:SRZN – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($11.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($9.92). Equities analysts anticipate that Surrozen will post -10.89 EPS for the current year.
Institutional Trading of Surrozen
A number of large investors have recently bought and sold shares of the business. Global Retirement Partners LLC acquired a new stake in Surrozen during the 3rd quarter worth $45,000. China Universal Asset Management Co. Ltd. grew its position in Surrozen by 37.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,000 shares of the company’s stock worth $160,000 after purchasing an additional 1,350 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in Surrozen in the first quarter valued at $350,000. Bank of New York Mellon Corp acquired a new position in Surrozen in the second quarter valued at $399,000. Finally, Renaissance Technologies LLC increased its stake in Surrozen by 117.1% in the first quarter. Renaissance Technologies LLC now owns 49,126 shares of the company’s stock valued at $1,431,000 after purchasing an additional 26,500 shares during the period. Institutional investors and hedge funds own 66.57% of the company’s stock.
Trending Headlines about Surrozen
These are some of the SRZN headlines that stood out recently:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $54 price target, signaling potential upside in the analyst’s view despite reduced earnings forecasts. HC Wainwright estimates and rating
- Negative Sentiment: Surrozen priced an underwritten offering of 1,894,540 common shares at $31.67 each, raising about $60 million before expenses. The new shares dilute existing shareholders and could weigh on the stock, while providing additional funding for the company. Surrozen announces offering pricing
- Negative Sentiment: HC Wainwright lowered its projected earnings per share across several future years, including estimates of losses of $12.01 for 2026 and $5.19 for 2027. The lower forecasts underscore continued expected losses, despite the firm’s Buy rating. HC Wainwright earnings estimates
Surrozen Company Profile
Surrozen, Inc. is a biotechnology company developing antibody-based medicines designed to activate the Wnt signaling pathway, which plays a role in tissue growth and repair. The company uses its proprietary platform to develop therapies intended to stimulate regeneration in specific tissues while limiting effects elsewhere in the body. Surrozen’s research has included candidates aimed at liver disease and inflammatory bowel disease, including SZN-043 and SZN-1326. Its work focuses on advancing potential treatments through research and clinical development; the company’s products are investigational and are not approved medicines.
Recommended Stories
- Five stocks we like better than Surrozen
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
